Orifarm Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Orifarm's estimated annual revenue is currently $287M per year.(i)
  • Orifarm's estimated revenue per employee is $201,000

Employee Data

  • Orifarm has 1428 Employees.(i)
  • Orifarm grew their employee count by 4% last year.

Orifarm's People

NameTitleEmail/Phone
1
General Manager CEE, VPReveal Email/Phone
2
Chief Facility Management TeamReveal Email/Phone
3
Head Marketing and BrandingReveal Email/Phone
4
Head productionReveal Email/Phone
5
Head sales teamReveal Email/Phone
6
Head material managementReveal Email/Phone
7
Head Sales RX AustriaReveal Email/Phone
8
Head Product LaboratoryReveal Email/Phone
9
Head QC Support LaboratoryReveal Email/Phone
10
Head Supply Planning and Delivery Dept.Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Orifarm?

Orifarm is a fast growing supplier of parallel imported and generic pharmaceuticals. We are an international company and our ambition is to supply high quality pharmaceuticals at low cost creating large savings for societies and consumers. In other words: we give people and societies more health care for their money! For more details please visit: www.orifarm.com

keywords:N/A

N/A

Total Funding

1428

Number of Employees

$287M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Orifarm News

2022-03-22 - Large, European medicine donation to Ukraine | EURACTIV PR

Orifarm, which is headquartered in Odense, Denmark, is going to receive all the medicine from the organization's member companies,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$300M14332%N/A
#2
$361.1M14332%N/A
#3
$458.1M14352%N/A
#4
$488.5M1436-2%N/A
#5
$201.3M14384%N/A